SCHEMBL16388491

SCHEMBL16388491

CC(C)(C)c1cnc(Nc2ccccc2)c(Nc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR4 P51679 1/20 0.49
▸ SYK P43405 2/20 0.44
▸ IGF1R P08069 2/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ MAPK8 P45983 2/20 0.42
▸ CDK1 P06493 2/20 0.42
▸ CDK2 P24941 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ GSK3B P49841 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ INSR P06213 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ FES P07332 1/20 0.42
▸ CSF1R P07333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27334137 0.85 BCL6 (0.45) CCR4SYKIGF1RJAK2MAPK8
SCHEMBL16388494 0.72 CDK1 (0.42) SYKIGF1RJAK2MAPK8CDK1
SCHEMBL16346475 0.72 MAPKAPK2 (0.43) SYKIGF1RJAK2MAPK8CDK1
SCHEMBL20850111 0.71 HPGD (0.50) CCR4SYKMAPK1MEN1ALDH1A1
SCHEMBL30069228 0.69 BCL6 (0.45) CCR4SYKIGF1RJAK2MAPK8
SCHEMBL16345981 0.69 IGF1R (0.40) SYKIGF1RJAK2MAPK8CDK1
SCHEMBL2037022 0.68 DHODH (0.57) SYKIGF1RJAK2MAPK8CDK1
Hydrochloric Acid SCHEMBL16346005 0.68 IGF1R (0.39) SYKIGF1RJAK2MAPK8CDK1
SCHEMBL13903883 0.66 MEN1 (0.69) MAPK8MAP4K4LCKRPS6KA3LIMK1
SCHEMBL820776 0.66 PDE10A (0.47) MEN1NPC1ALDH1A1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200251667-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES UDC IRELAND LTD (IE) 2020-08-06 — — US disclosed
EP-3608329-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES UDC Ireland Limited (IE) 2020-02-12 — — EP disclosed
EP-3266789-B1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES UDC IRELAND LTD (IE) 2019-09-25 — — EP disclosed
EP-3016960-B1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES UDC IRELAND LTD (IE) 2017-04-26 — — EP disclosed
US-20160372687-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES BASF SE (DE) 2016-12-22 — — US disclosed
US-20160372687-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES BASF SE (DE) 2016-12-22 — — US disclosed
WO-2015000955-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES BASF SE (DE) 2015-01-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200251667-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES DDT, OCIAD1, OCIAD2 CCR4 1200/4885SYK 2978/4885IGF1R 1949/4885
US-20160372687-A1 MONOSUBSTITUTED DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES FOR USE IN ORGANIC LIGHT EMITTING DIODES DDT, OCIAD1, OCIAD2 CCR4 1200/4885SYK 2978/4885IGF1R 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback